- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04239144
Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease
Role of Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease - Pilot Study Randomized Controlled Trial
Ventricular tachycardia (VT) is the main cause of sudden death in patients with structural heart diseases. The use of ICD (implantable cardio-defibrillator) could prevent sudden death, however, the occurrence of repetitive shock decreases significantly the quality of life and could increase the mortality rate. Chagas disease in our environment is the most common heart disease and often associated with the occurrence appropriate ICD therapies.
The chronic treatment of VT aims to prevent recurrences with the use of antiarrhythmic drugs and catheter ablation, but in many cases, these treatments are insufficient to control the VT. Cardiac Sympathetic Denervation by bilateral sympathectomy has been described as an alternative treatment of VT refractory to medical treatment and radiofrequency ablation, especially in patients with channelopathies. This treatment could have a role in patients with structural heart disease.
The objective of this study is to evaluate the efficacy of the bilateral sympathectomy in the reduction of ventricular tachycardia in patients with Chagas cardiomyopathy. In this pilot study, the investigators will select 45 patients with Chagas cardiomyopathy with ICD who presented at least four ICD therapies in the prior six months. These patients will be randomly assigned to three groups, 15 patients in medical therapy group, 15 in catheter ablation and 15 in bilateral sympathectomy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVE
Primary
• Evaluate the efficacy of bilateral sympathectomy in the reduction of VT episodes in patients with Chagas cardiomyopathy.
Secondary
- To compare the efficacy of bilateral sympathectomy against VT ablation and against optimal medical therapy.
- To evaluate the density of ventricular premature beats 24-hour Holter and monitor the events recorded by the ICD and the impact of the treatment performed.
- To evaluate the length of the hospital stay according to the type of intervention.
- To evaluate the rate of clinical complications according to the type of intervention.
- To evaluate the impact of treatment on left ventricular function.
Follow up
Outcomes Assessment in six months and one year
- Recurrence rate of appropriate therapies;
- Density of ventricular ectopies;
- Complication rates per type of intervention;
- Number of in-hospital days per type of intervention;
- Assessment of LV function;
METHODS
This is a pilot, single-centre, open-label, randomized trial in patients with Chagas disease and multiple appropriate ICD therapies. This study consists of three groups: (1) medical treatment, (2) catheter ablation and (3) bilateral sympathectomy, being included 15 patients in each group.
Inclusion Criteria:
- Patients with Chagas Disease Cardiomyopathy having an ICD
- At least four appropriate ICD therapies in the past six months, documented by device interrogation or medical records;
- Use of amiodarone and beta blockers in an optimized fashion;
- Life expectancy of more than one year
- Conditions for following the plan of clinical follow-up of the study.
Exclusion criteria:
- Presence of an absolute contraindication to receive any of the possible treatments of the study;
- Pregnant Woman;
- Less than 18 years-old;
- Renal insufficiency with creatinine >2.5 mg/dL (221 umol/L);
- Mobile thrombus in the left ventricle;
- Left Ventricle Ejection fraction < 10%;
- Unstable angina;
- Severe aortic stenosis
- Primary severe mitral insufficiency;
- New York Heart Association (NYHA) functional class IV;
- Previous cardiac surgery or scheduled.
The patients will be recruited consecutively in the outpatient clinic of Cardiac Pacing Unit, or in outpatient clinic of Arrhythmias Clinical Unit or in the Emergency Clinical Unit.
Group 1 - Medical Treatment: patients allocated to this group will receive amiodarone reimpregnation, incremental dose of beta-blocker and if possible ICD reprogramming.
Group 2 - Catheter ablation: patients allocated to this group will undergo epicardial and endocardial catheter ablation with the use of an irrigated contact sensor tip catheter. Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced, activation mapping will also be performed. The aim of the ablation is to eliminate the clinical VT additionally to substrate modification. The result of ablation will be defined as (1) complete success (all VTs non-inducible); (2) partial success (clinical VT non inducible, but other morphologies still inducible) and (3) failure (clinical VT still inducible).
Group 3 - Bilateral sympathectomy - bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason. Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers. After the application, 10 ml of 0.25% bupivacaine solution will be injected along the site of the pleural dissection for postoperative analgesia. The lung will be reinflated under direct vision and a small tube will be inserted to remove the air through the upper incision, which will be removed at the end of the operation if possible. The two port sites will be closed primarily with absorbable stitches.
The study conformed to the principles outlined in the Declaration of Helsinki and was approved by the ethics committee and institutional review board of our hospital. All patients will provide written informed consent before randomization.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Paulo M Pego Fernandes, PhD
- Phone Number: +551126615921
- Email: paulo.fernandes@incor.usp.br
Study Contact Backup
- Name: Rodrigo M Kulchetscki, MD
- Phone Number: +551198246-8680
- Email: r.kulchetscki@gmail.com
Study Locations
-
-
-
Sao Paulo, Brazil, 05403-900
- Recruiting
- Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
-
Principal Investigator:
- Mauricio I Scanavacca, MD, PhD
-
Sub-Investigator:
- Cristiano F Pisani, MD, PhD
-
Contact:
- Gabriela Faria, Assistant
- Phone Number: +551126615921
- Email: gabriela.faria@incor.usp.br
-
Sub-Investigator:
- Martino Martinelli Filho, MD, PhD
-
Contact:
- Rodrigo M Kulchetscki, MD
- Phone Number: +5511982468680
- Email: r.kulchetscki@gmail.com
-
Principal Investigator:
- Rodrigo M Kulchetscki, MD
-
Sub-Investigator:
- Muhieddine O Chokr, MD, PhD
-
Sub-Investigator:
- Lucas G Moura, MD
-
Sub-Investigator:
- Gabriela Faria, DNP
-
Sub-Investigator:
- Sergio F Siqueira, ENG
-
Principal Investigator:
- Paulo Manoel Pego Fernandes, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with Chagas Disease Cardiomyopathy having an ICD
- At least four appropriate ICD therapies in the past six months, documented by device interrogation or medical records;
- Use of amiodarone and beta blockers in an optimized fashion;
- Life expectancy of more than one year
- Conditions for following the plan of clinical follow-up of the study.
Exclusion criteria:
- Presence of an absolute contraindication to receive any of the possible treatments of the study;
- Pregnant Woman;
- Less than 18 years-old;
- Renal insufficiency with creatinine >2.5 mg/dL (221 umol/L);
- Mobile thrombus in the left ventricle;
- Left Ventricle Ejection fraction < 10%;
- Unstable angina;
- Severe aortic stenosis
- Primary severe mitral insufficiency;
- New York Heart Association (NYHA) functional class IV;
- Previous cardiac surgery or scheduled.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Medical therapy group
Arm 1 - 15 patients allocated to this group will receive conventional antiarrhythmic medical treatment according the guidelines with additional impregnation of amiodarone, incremental dose of beta-blocker and if possible ICD reprograming.
|
|
Active Comparator: Catheter ablation
Intervention Arm 2 -15 patients allocated to this group will undergo epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter.
Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced, activation mapping will also be performed.
The result of ablation will be defined as (1) complete success (all VTs non-inducible); (2) partial success (clinical VT non inducible, but other morphologies still inducible) and (3) failure (clinical VT still inducible).
|
Catheter ablation - patients allocated to this group will undergone epicardial and endocardial catheter ablation with the use of irrigated contact sensor tip catheter.
Voltage electroanatomical mapping using Carto System will be performed in all cases and if hemodynamically stable VT is induced activation mapping will also be performed.
The aim of the ablation is to eliminate the clinical VT additionally to substrate modification.
The result of ablation will be defined as (1) complete success; (2) partial success and (3) failure.
|
Experimental: Bilateral sympathectomy
Interventional Arm 3 - 15 patients allocated to this group will undergo bilateral sympathectomy, which will be performed using video assisted thoracoscopy using the Ethicon Ultracision device.
The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches.
The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason.
Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers.
|
Bilateral sympathectomy will be performed using video assisted thoracoscopy using the Ethicon Ultracision device.
The denervation consisted of left lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches.
The cephalic portion of the stellate ganglion was preserved to avoid Horner's syndrome and the electrocautery use was also avoided due to the same reason.
The nerve was blocked using Ultracision device to avoid thermic lesion of the stellate ganglion.
Hemodynamic and echocardiographic behaviors were continuously monitored during these surgical maneuvers.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Ventricular Tachycardia Recurrence
Time Frame: 12 months
|
Compare the time to the first documented Ventricular Tachycardia episode between groups
|
12 months
|
Burden of Ventricular Tachycardia Recurrence
Time Frame: 12 months
|
Compare the number of Ventricular Tachycardia episodes between groups in 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventricular Tachycardia Recurrence Following Sympathectomy Compared to Catheter Ablation.
Time Frame: 12 months
|
Time to first VT episode after sympathectomy compared to Catheter ablation
|
12 months
|
Mortality and Transplant Rate
Time Frame: 12 months
|
To compare between groups the number of patients who died or received a cardiac transplant at the end of the follow-up
|
12 months
|
Ventricular Ectopic Beats Density
Time Frame: 12 months
|
To evaluate the density of ventricular premature beats in the 24-hour Holter in the follow-up, for each group.
|
12 months
|
Length of Hospital Stay
Time Frame: 12 months
|
Compare the number of in-hospital days according to the type of intervention.
|
12 months
|
Rate of Complications Following Intervention
Time Frame: 12 months
|
Compare the rate of clinical complications according to the type of intervention.
|
12 months
|
Impact on Left Ventricular Ejection Fraction
Time Frame: 12 months
|
To evaluate the variations of the Left Ventricular Ejection Fraction in each group.
|
12 months
|
Autonomic Measures
Time Frame: 12 months
|
To compare the RR variability measures in the 24h-Holter between groups
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Paulo M Pego Fernandes, MD, PhD, Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)
- Study Director: Maurício I Scanavacca, MD, PhD, Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)
- Principal Investigator: Rodrigo M Kulchetscki, MD, Instituto do Coração Faculdade de Medicina da USP - (INCOR-FMUSP)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 49701215.2.0000.0068
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chagas Cardiomyopathy
-
University of Sao Paulo General HospitalInCor Heart InstituteRecruiting
-
Hospital de Niños R. Gutierrez de Buenos AiresCompletedChagas Cardiomyopathy | Chagas DiseaseArgentina
-
Fundación Cardioinfantil Instituto de CardiologíaInstituto de Corazón de BucaramangaUnknown
-
Federal University of Minas GeraisCompletedChagas Disease | Exercise Training | CardiomyopathyBrazil
-
National Institute of Cardiology, Laranjeiras,...CompletedChagas CardiomyopathyBrazil
-
Hospital Sao RafaelCompleted
-
Evandro Chagas Institute of Clinical ResearchAndrea Silvestre de Sousa, MD PhD; Pedro Emmanuel Alvarenga Americano do Brasil... and other collaboratorsCompletedChagas CardiomyopathyBrazil
-
University of Sao PauloNational Institute of Allergy and Infectious Diseases (NIAID); Federal University... and other collaboratorsCompleted
-
Evandro Chagas National Institute of Infectious...Completed
-
Federal University of Minas GeraisCompletedHeart Failure | Chagas Cardiomyopathy | Dilated CardiomyopathyBrazil
Clinical Trials on Catheter ablation
-
Charles University, Czech RepublicRecruitingAtrial FibrillationCzechia
-
Sheba Medical CenterMedtronicUnknownPremature Ventricular Contraction
-
Oxford University Hospitals NHS TrustRoyal Bournemouth and Christchurch Hospitals NHS Foundation TrustCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompletedAtrial Fibrillation | Paroxysmal Atrial FibrillationUnited States, France, Italy, Canada, Czechia
-
Emory UniversityBoston Scientific CorporationCompleted
-
Field MedicalNot yet recruitingVentricular Tachycardia | Ventricular Arrythmia | Ventricular Tachyarrhythmia | PVC - Premature Ventricular Complex | PVC - Premature Ventricular ContractionCzechia
-
The Cleveland ClinicAtriCure, Inc.Not yet recruitingHeart Failure | Atrial FibrillationUnited States
-
Medtronic Bakken Research CenterTerminatedAtrial FibrillationNetherlands
-
Deutsches Herzzentrum MuenchenCompleted
-
Erasmus Medical CenterUnknownTachycardia, Supraventricular | Tachycardia; Paroxysmal, SupraventricularNetherlands